2018 Q1 Form 10-Q Financial Statement
#000156459018011781 Filed on May 08, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $64.00K | $64.00K |
| YoY Change | 0.0% | 0.0% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $1.971M | $2.060M |
| YoY Change | -4.32% | -18.67% |
| % of Gross Profit | ||
| Research & Development | $5.326M | $4.020M |
| YoY Change | 32.49% | -15.24% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.000K | $1.000K |
| YoY Change | 0.0% | -66.67% |
| % of Gross Profit | ||
| Operating Expenses | $7.297M | $6.080M |
| YoY Change | 20.02% | -16.44% |
| Operating Profit | -$7.233M | -$6.016M |
| YoY Change | 20.23% | -16.58% |
| Interest Expense | $379.0K | $345.0K |
| YoY Change | 9.86% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | $3.231M | $1.147M |
| YoY Change | 181.69% | 3996.43% |
| Pretax Income | -$4.000M | -$4.870M |
| YoY Change | -17.86% | -32.17% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$4.002M | -$4.869M |
| YoY Change | -17.81% | -32.22% |
| Net Earnings / Revenue | -6253.13% | -7607.81% |
| Basic Earnings Per Share | -$0.12 | -$0.19 |
| Diluted Earnings Per Share | -$0.12 | -$0.25 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 33.58M | 25.36M |
| Diluted Shares Outstanding | 33.58M | 25.56M |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $63.70M | $54.90M |
| YoY Change | 16.03% | 44.47% |
| Cash & Equivalents | $27.55M | $19.91M |
| Short-Term Investments | $36.50M | $35.00M |
| Other Short-Term Assets | $92.00K | $138.0K |
| YoY Change | -33.33% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $64.30M | $55.59M |
| YoY Change | 15.67% | 39.25% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | ||
| YoY Change | ||
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.100M | $730.0K |
| YoY Change | 50.68% | 70.16% |
| Total Long-Term Assets | $1.188M | $1.065M |
| YoY Change | 11.55% | 40.13% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $64.30M | $55.59M |
| Total Long-Term Assets | $1.188M | $1.065M |
| Total Assets | $65.49M | $56.66M |
| YoY Change | 15.59% | 39.27% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.331M | $2.044M |
| YoY Change | 62.96% | 48.12% |
| Accrued Expenses | $937.0K | $1.057M |
| YoY Change | -11.35% | -58.94% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $3.599M | |
| YoY Change | ||
| Total Short-Term Liabilities | $10.90M | $3.358M |
| YoY Change | 224.6% | -33.39% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $11.16M | $14.35M |
| YoY Change | -22.21% | |
| Other Long-Term Liabilities | $6.600M | $5.400M |
| YoY Change | 22.22% | 800.0% |
| Total Long-Term Liabilities | $11.16M | $14.35M |
| YoY Change | -22.21% | 2292.0% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $10.90M | $3.358M |
| Total Long-Term Liabilities | $11.16M | $14.35M |
| Total Liabilities | $28.64M | $23.12M |
| YoY Change | 23.88% | 310.18% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$209.3M | -$185.1M |
| YoY Change | 13.07% | 17.63% |
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $36.84M | $33.53M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $65.49M | $56.66M |
| YoY Change | 15.59% | 39.27% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$4.002M | -$4.869M |
| YoY Change | -17.81% | -32.22% |
| Depreciation, Depletion And Amortization | $1.000K | $1.000K |
| YoY Change | 0.0% | -66.67% |
| Cash From Operating Activities | -$8.219M | -$6.772M |
| YoY Change | 21.37% | -24.42% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $10.00K | $2.000K |
| YoY Change | 400.0% | -85.71% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$4.000M | -$12.16M |
| YoY Change | -67.11% | |
| Cash From Investing Activities | -$4.005M | -$12.16M |
| YoY Change | -67.07% | 86778.57% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $30.19M | $3.277M |
| YoY Change | 821.33% | |
| Debt Paid & Issued, Net | $0.00 | |
| YoY Change | ||
| Cash From Financing Activities | 28.31M | 3.187M |
| YoY Change | 788.17% | 63640.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -8.219M | -6.772M |
| Cash From Investing Activities | -4.005M | -12.16M |
| Cash From Financing Activities | 28.31M | 3.187M |
| Net Change In Cash | 16.08M | -15.75M |
| YoY Change | -202.12% | 75.58% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$8.219M | -$6.772M |
| Capital Expenditures | $10.00K | $2.000K |
| Free Cash Flow | -$8.229M | -$6.774M |
| YoY Change | 21.48% | -24.52% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Assets
Assets
|
65488000 | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
45850000 | |
| CY2018Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3331000 | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3833000 | |
| CY2018Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
937000 | |
| CY2018Q1 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
230000 | |
| CY2017Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
314000 | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5326000 | |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1705000 | |
| CY2018Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
257000 | |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
257000 | |
| CY2018Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
3599000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
4349000 | |
| CY2018Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
2728000 | |
| CY2017Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | |
| CY2018Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
6571000 | |
| CY2018Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
11164000 | |
| CY2018Q1 | us-gaap |
Liabilities
Liabilities
|
28644000 | |
| CY2018Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q1 | us-gaap |
Preferred Stock Value Outstanding
PreferredStockValueOutstanding
|
0 | |
| CY2018Q1 | us-gaap |
Common Stock Value Outstanding
CommonStockValueOutstanding
|
47000 | |
| CY2018Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
246049000 | |
| CY2018Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-209252000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
36844000 | |
| CY2018Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
65488000 | |
| CY2018Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
125000000 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
46843441 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
46843441 | |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
64000 | |
| CY2018Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1971000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
7297000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7233000 | |
| CY2018Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
111000 | |
| CY2018Q1 | us-gaap |
Interest Income Other
InterestIncomeOther
|
167000 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
379000 | |
| CY2018Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-3554000 | |
| CY2018Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3231000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4002000 | |
| CY2017Q1 | scyx |
Warrant Liability Fair Value Adjustment On Net Loss
WarrantLiabilityFairValueAdjustmentOnNetLoss
|
1523000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-4002000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-6392000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.12 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.12 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.25 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
33579025 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25364429 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
33579025 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
25562027 | |
| CY2018Q1 | us-gaap |
Depreciation
Depreciation
|
1000 | |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
1000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
425000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
396000 | |
| CY2018Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
58000 | |
| CY2017Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-100000 | |
| CY2018Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
111000 | |
| CY2017Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
100000 | |
| CY2018Q1 | scyx |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-4000 | |
| CY2017Q1 | scyx |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-5000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-422000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
549000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1496000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-359000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-64000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-64000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8219000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6772000 | |
| CY2018Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
11980000 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
6000000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
10000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
15975000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
18161000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4005000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-12163000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
30192000 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3277000 | |
| CY2018Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1906000 | |
| CY2017Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
108000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
20000 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
|
18000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
28306000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3187000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
16082000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-15748000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11469000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
35656000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
27551000 | |
| CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
19908000 | |
| CY2018Q1 | us-gaap |
Interest Paid
InterestPaid
|
379000 | |
| CY2017Q1 | us-gaap |
Interest Paid
InterestPaid
|
345000 | |
| CY2018Q1 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
128000 | |
| CY2017Q1 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
60000 | |
| CY2018Q1 | scyx |
Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
|
224000 | |
| CY2018Q1 | scyx |
Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
|
84000 | |
| CY2017Q1 | scyx |
Deferred Offering Costs Reclassified To Additional Paid In Capital
DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital
|
10000 | |
| CY2018Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:6pt;margin-top:6pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.79%;">Concentration of Credit Risk</p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.79%;">Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with one bank which exceed FDIC insured limits and certain short-term investments. Ongoing credit evaluations of the customer’s financial condition are performed and independent credit ratings for the associated counterparties are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such account.</p></div> | |
| CY2018Q1 | us-gaap |
Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
|
<div> <p style="margin-bottom:6pt;margin-top:6pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.79%;">Revenue Recognition and Deferred Revenue</p> <p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.79%;">The Company has entered into arrangements involving the sale or license of intellectual property and the provision of other services. When entering into any arrangement involving the sale or license of intellectual property rights and other services, the Company determines whether the arrangement is subject to accounting guidance in ASC 606, <font style="font-style:italic;">Revenue from Contracts with Customers </font>(“Topic 606”), which became effective in the current period (the Company has elected to use the modified retrospective approach for contracts that are not completed contracts and there was no cumulative adjustment recognized in the current period) as well as ASC 808, <font style="font-style:italic;">Collaborative Arrangements </font>("Topic 808"). If the Company determines that an arrangement includes goods or services that are central to the Company’s business operations for consideration, the Company will then identify the performance obligations in the contract using the unit-of-account guidance in Topic 606. For a distinct unit-of-account that is within the scope of Topic 606, the Company applies all of the accounting requirements in Topic 606 to that unit-of-account, including the recognition, measurement, presentation and disclosure requirements. For a distinct unit-of-account that is not within the scope of Topic 606, the Company will recognize and measure the distinct unit-of-account based on other authoritative ASC Topics or on a reasonable, rational, and consistently applied policy election.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analyzing the arrangement to identify performance obligations requires the use of judgment. In arrangements that include the sale or license of intellectual property and other promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other services into a single performance obligation. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies non-refundable upfront payments, milestone payments and royalties received for the sale or license of intellectual property as revenues within its statements of operations because the Company views such activities as being central to its business operations. For the sale of intellectual property that is distinct, fixed consideration and variable consideration are included in the transaction price and recognized in revenue immediately to the extent that it is probable that there would not be a significant reversal of cumulative revenue in the future. For the license of intellectual property that is distinct, fixed and variable consideration (to the extent there will not be a significant reversal in the future) are also recognized immediately in income, except for consideration received in the form of royalty or sales-based milestones, which is recorded when the customer’s subsequent sales or usages occur. If the sale or license of intellectual property is not distinct, revenue is deferred and recognized over the estimated period of the Company’s combined performance obligation. For contractual arrangements that meet the definition of a collaborative arrangement under Topic 808, consideration received for any units-of-account that are outside the scope of Topic 606 are recognized in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014 (the “R-Pharm Agreement”), is a collaborative arrangement pursuant to Topic 808. The Company received a non-refundable upfront payment of $1.5 million from R-Pharm in August 2013 which is being recognized over the estimated relationship period of 70 months for the combined performance obligation that includes the license of intellectual property and the participation on a joint steering committee. The Company recognized revenue from this upfront payment of $0.1 million for the three months ended March 31, 2018 and 2017. The Company is entitled to receive other payments under the R-Pharm Agreement including development and sales-based milestones and royalties; however, the variable consideration was fully constrained as of March 31, 2018. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $0.3 million as of March 31, 2018 and December 31, 2017, which are presented in prepaid expenses and other current assets in the accompanying balance sheets.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:4.79%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into an Asset Purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the Asset Purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. <font style="color:#000000;">For the three months ended March 31, 2018, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2018. Additionally, in October 2014 we entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone and for the three months ended March 31, 2018, there was no revenue recognized by the Company associated with this agreement.</font></p></div> | |
| CY2018Q1 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
5000 | |
| CY2018Q1 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
6000 | |
| CY2015Q4 | scyx |
Shelf Registration Maximum Equity Offering Price
ShelfRegistrationMaximumEquityOfferingPrice
|
150000000 | |
| CY2013Q3 | us-gaap |
Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
|
1500000 | |
| CY2013Q3 | scyx |
Deferred Revenue Estimated Performance Period
DeferredRevenueEstimatedPerformancePeriod
|
P70M | |
| CY2018Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
100000 | |
| CY2017Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
100000 | |
| CY2018Q1 | us-gaap |
Nontrade Receivables Current
NontradeReceivablesCurrent
|
251000 | |
| CY2017Q4 | us-gaap |
Nontrade Receivables Current
NontradeReceivablesCurrent
|
251000 | |
| CY2018Q1 | scyx |
Researchand Development Expense Gross
ResearchandDevelopmentExpenseGross
|
5326000 | |
| CY2017Q1 | scyx |
Researchand Development Expense Gross
ResearchandDevelopmentExpenseGross
|
4039000 | |
| CY2018Q1 | scyx |
Researchand Development Income Reimbursement
ResearchandDevelopmentIncomeReimbursement
|
0 | |
| CY2017Q1 | scyx |
Researchand Development Income Reimbursement
ResearchandDevelopmentIncomeReimbursement
|
19000 | |
| CY2018Q1 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
36477000 | |
| CY2018Q1 | us-gaap |
Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
|
P11Y | |
| CY2018Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7300000 | |
| CY2018Q1 | us-gaap |
Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
|
P5Y | |
| CY2018Q1 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
36476000 | |
| CY2018Q1 | scyx |
Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
|
48000 | |
| CY2017Q4 | scyx |
Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
|
384000 | |
| CY2018Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
96000 | |
| CY2017Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
279000 | |
| CY2018Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
158000 | |
| CY2017Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
62000 | |
| CY2018Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
92000 | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
91000 | |
| CY2018Q1 | scyx |
Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
|
355000 | |
| CY2017Q4 | scyx |
Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
|
609000 | |
| CY2018Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
261000 | |
| CY2017Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
763000 | |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
32000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
29000 | |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
289000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
304000 | |
| CY2018Q1 | scyx |
Lease Agreement Area Of Office Space
LeaseAgreementAreaOfOfficeSpace
|
19275 | |
| CY2018Q1 | us-gaap |
Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
|
The Company has the option to renew for two consecutive five-year periods from the end of the first term. Under the lease, the Company must furnish a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease | |
| CY2018Q1 | us-gaap |
Security Deposit
SecurityDeposit
|
300000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
55000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
510000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
498000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
508000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
518000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
529000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
4919000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
7482000 | |
| CY2018Q1 | scyx |
Number Of License Agreements
NumberOfLicenseAgreements
|
2 | |
| CY2018Q1 | scyx |
Additional Milestone Payments Maximum
AdditionalMilestonePaymentsMaximum
|
2300000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
425000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
20000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
18998000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
-7000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
4152734 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
3075994 | |
| CY2018Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
14033 | |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
14033 | |
| CY2018Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
30442386 | |
| CY2017Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
8012211 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
17751500 | |
| CY2018Q1 | scyx |
Fair Value Of Liabilities
FairValueOfLiabilities
|
9300000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3075994 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1111470 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
34730 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4152734 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1859894 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4152734 | |
| CY2018Q1 | scyx |
Derivative Fair Value Gain Loss From Mark To Market Adjustment
DerivativeFairValueGainLossFromMarkToMarketAdjustment
|
3554000 | |
| CY2018Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
9299000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.59 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.76 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
4.53 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.57 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
6.73 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
4.57 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y2M23D | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M5D | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P5Y10M14D | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y8M5D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
151000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
0 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
0 | |
| CY2018Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | |
| CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
3872000 |
